Abstract
Background Use of digital sensors to passively collect long-term offers a step change in our ability to screen for early signs of disease in the general population. Smartwatch data has been shown to identify Parkinson’s disease (PD) several years before the clinical diagnosis, however, has not been evaluated in comparison to biological and pathological markers such as dopaminergic imaging (DaTscan) or cerebrospinal fluid (CSF) alpha-synuclein seed amplification assay (SAA) in an at-risk cohort.
Methods To address this, we performed a cohort study using longitudinal clinical assessment data from the Parkinson’s Progression Marker Initiative (PPMI) cohort collected between 2010 and 2020 with additional long-term (mean: 485 days) at-home digital monitoring data (collected 2018-2020) from the Verily Study Watch. We derived a digital risk score and evaluated it in an at-risk cohort (N = 109) consisting of people with genetic markers (LRRK2, GBA) or prodromal symptoms (hyposmia, polysomnography-proven Rapid-Eye-Movement behavioral sleep disorder) without a diagnosis of PD for whom all modalities were available (digital, DaTscan, SAA). The digital risk score was compared to the Movement Disorder Society (MDS) research criteria for prodromal PD, alpha-synuclein SAA and DaTscan.
Findings In the at-risk cohort (N=109, mean age = 64.62±6.86, 37% male), the digital risk correlated with the MDS research criteria for prodromal PD (r = 0.36, p-value = 1.46x10-4) and was increased in individuals with subthreshold Parkinsonism (UPDRS III > 6) (p-value = 4.99x10-6) and hyposmia (p-value = 3.77x10-2). Notably, the digital risk was correlated with DaTscan putamen binding ratio (r = -0.32, p-value = 6.64x10-4) and CSF SAA (r = 0.2, p-value = 3.9x10-2). The digital risk achieved higher sensitivity in identifying people with SAA positivity (0.71 vs 0.43) or DaTscan positivity (0.43 vs 0.14) than the MDS prodromal score but performed on-par or worse than hyposmia (SAA+: 0.71 vs 0.71, DaT+: 0.48 vs 0.57).
Interpretation A digital risk score from smartwatch data could be used as a sensitive screening tool for early detection of PD followed by more specific tests.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PPMI, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics. A.-K.S. was supported by a PhD studentship funded by the Welsh Government through Health and Care Research Wales (HS-20-11). C.S., P.B., and V.E.-P. are supported by the UK Dementia Research Institute funded by the Medical Research Council (MRC), Alzheimer's Society and Alzheimer's Research UK. C.S. is supported by a UK Dementia Research Institute (UK DRI) Future Leaders Fellowship [MR/MR/X032892/1]. The lectureship position for C.S. is supported by the Edmond J. Safra Foundation. C.S. received funding from the Ser Cymru II programme (CU187) which is part-funded by Cardiff University and the European Regional Development Fund through the Welsh Government. K.P. is funded by an MRC Clinician-Scientist Fellowship (MR/P008593/1) and a Transition Support Award (MR/V036084/1). V.E.-P. is funded by Joint Programming for Neurodegeneration (MRC: MR/T04604X/1), and Dementia Platforms UK (MRC: MR/L023784/2). N.H. has nothing to declare.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis used DaTscan and alpha-synuclein SAA results for at-risk participants, obtained from PPMI upon request after approval by the PPMI Data Access Committee. Data used in the preparation of this article were obtained in November 2022 from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data), RRID:SCR_006431. Sequestered data was given access to October 2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This analysis used DaTscan and alpha-synuclein SAA results for at-risk participants, obtained from PPMI upon request after approval by the PPMI Data Access Committee. Data used in the preparation of this article were obtained in November 2022 from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data), RRID:SCR_006431. Sequestered data was given access to October 2023.
https://www.ppmi-info.org/access-data-specimens/download-data
